Net Revenues Rise, Net Loss Narrows Compared to Prior Year; Operating Loss
IRVINE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, today reported higher revenue, a 26 percent decline in operating loss, and narrower net loss for the third quarter ended September 30, 2008.
Total revenues for the third quarter of 2008 were $7.6 million,
compared to $7.3 million in the third quarter of 2007. Domestic probe
sales, as well as the estimated number of domestic cryoablation procedures
performed, in the third quarter and the first nine months of 2008 and 2007
are summarized in the following table:
Three Months Ended Nine Months Ended
September 30, September 30,
2008 2007 2008 2007
Estimated domestic cryoablation
procedures 2,263 2,353 7,122 7,104
Number of cryoprobes sold:
Straight probes 8,660 9,957 28,017 29,852
Right-angle probes 2,084 1,564 6,058 4,637
Total 10,744 11,521 34,075 34,489
Probe sales are reported in two categories: straight probes, which are typically, although not always, used in prostate procedures and right-angle probes, which are typically used in procedures other than prostate procedures.
Gross margin in the third quarter
|SOURCE Endocare, Inc.|
Copyright©2008 PR Newswire.
All rights reserved